PMID: 2864374Aug 1, 1985Paper

Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group

Journal of Hypertension

Abstract

Myocardial infarction, sudden cardiac death, cerebrovascular accidents, blood pressure control and treatment tolerability were studied in a randomized double-blind trial conducted in 6357 men and women aged 40-64 years with uncomplicated essential hypertension (diastolic blood pressures 100-125 mmHg). At the start of the trial 3185 patients received treatment based on a beta-blocker (oxprenolol), while in the remaining 3172 placebo replaced oxprenolol. Supplementary drugs, excluding beta-blockers, were used as necessary in both treatment groups, with the aim of reducing diastolic pressure to 95 mmHg or less. Patients were followed for 3-5 years, a total of 25 651 patient years at risk. In most respects the two groups fared equally well; sudden death (relative risk [RR] 1.08; 95% confidence interval [Cl] 0.68 and 1.72), myocardial infarction (RR 0.83; Cl 0.59 and 1.16) and cerebrovascular accident (RR 0.97; Cl 0.64 and 1.47) rates were similar. Beta-blocker based therapy was associated with significantly lower average blood pressures, earlier ECG normalization, less hypokalaemia and fewer withdrawals from double-blind treatment for uncontrolled hypertension. Doctor-elicited and patient-assessed unwanted effects demonstrated over...Continue Reading

Citations

Dec 1, 1992·Cardiovascular Drugs and Therapy·J I Robertson
Oct 1, 1989·Cardiovascular Drugs and Therapy·J R Hampton
Nov 1, 1987·Journal of General Internal Medicine·C H Hennekens
Oct 16, 2002·Current Cardiology Reports·Ehud Grossman, Franz H Messerli
May 25, 2007·Current Heart Failure Reports·David M Wild, Marrick Kukin
Sep 10, 2013·Current Heart Failure Reports·Justin L Grodin, W H Wilson Tang
Jun 18, 2011·Current Hypertension Reports·Debbie L Cohen, Raymond R Townsend
Oct 1, 1987·American Heart Journal·B N Prichard, B Tomlinson
Jan 29, 1988·The American Journal of Medicine·C J Bulpitt, A E Fletcher
Jan 1, 1989·Pharmacology & Therapeutics·J M Cruickshank, J C Smith
Jan 1, 1995·Archives of Gerontology and Geriatrics·E Ambrosioni, S Bacchelli
Jan 1, 1989·Social Science & Medicine·T ChristiansenC Svarer
Dec 1, 1989·Journal of the American College of Cardiology·G L Bakris, E D Frohlich
Jul 1, 1991·Trends in Cardiovascular Medicine·K O'Malley, J G Kelly
Mar 1, 1997·Progress in Cardiovascular Diseases·J B SorianoD E Grobbee
Oct 26, 1985·Lancet
Mar 14, 1987·Lancet·J M CruickshankF J Zacharias
May 16, 1987·Lancet·G Berglund, O Samuelsson
Mar 1, 2002·Journal of the American College of Cardiology·Paolo VerdecchiaGiuseppe Ambrosio
Aug 8, 2001·Journal of Evaluation in Clinical Practice·J I Robertson
Jan 23, 1992·The New England Journal of Medicine·A E Fletcher, C J Bulpitt
Sep 18, 2010·European Heart Journal·Sripal BangaloreUNKNOWN Treating to New Targets Steering Committee and Investigators
May 1, 1993·British Journal of Clinical Pharmacology·G FowlerJ C Petrie
Jan 31, 2003·The Journal of Clinical Hypertension·Ji-Guang Wang, Jan A Staessen
Aug 19, 2008·International Journal of Clinical Practice·H Krum
Sep 22, 2000·The American Journal of Chinese Medicine·J SungB H Oh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.